Historical, register-based cohort study following 85 patients in the course of a time frame extending from 2 years before to 2 years after trauma occurrence.
To investigate the cost-effectiveness of surgery versus conservative management for thoracolumbar burst fractures.
Despite the prevalence of thoracolumbar burst fractures, consensus has still not been reached in terms of their clinical management and whereas from a health policy point of view, efficient use of resources is equally important, literature pertaining to this aspect is limited.
Consecutive patients who were admitted to a university clinic between 2004 and 2008 because of CT-verified AO type A3 fractures (T11-L2), age 18 to 65 years Patients with neurological compromise, osteoporosis, or malignancy were not included. The cost parameter defined primary and secondary health-care use (2010 €) and the effect parameter was based on three alternative measures of pain medication: morphine milligram and defined daily doses (DDD) of narcotic and nonnarcotic analgesics. For cost-effectiveness analysis, we employed a difference-in-difference approach, including control for treatment selection (age, sex, and fracture type). Nonparametric bootstrapping was used to estimate conventional 95% confidence intervals of mean estimates.
When taking into consideration all health-care consumption, surgical management was observed to cost an additional €10,734 (4215; 15,144) as compared with conservative management. The differences on morphine at 527(–3031; 6,016) milligram, narcotic analgesics at –8(–176; 127) DDD, and nonnarcotic analgesics at –3(–72; 58) DDD were all insignificant The probability for surgery being cost-effective did not exceed 50% for any value of willingness to pay for effect.
Surgical management does not seem to be a cost-effective strategy as compared with conservative management for traumatic thoracolumbar burst fractures without neurological deficits. In addition, higher-volume studies examining the clinical effect of alternative management strategies would be valuable.
Level of Evidence: 3
*Aarhus University Hospital Orthopedic Spinal Research Laboratory, Aarhus, Denmark
†Department of Orthopedic Surgery, Aarhus University Hospital, Aarhus, Denmark
‡Health Economics, Department for Public Health, Aarhus University, Denmark
§Department of Clinical Medicine, Aarhus University, Denmark.
Address correspondence and reprint requests to Efe Levent Aras, MD, Aarhus University Hospital Spinal Research Laboratory, Noerrebrogade 44, Building 1A, 8000 Aarhus, Denmark; E-mail: email@example.com;firstname.lastname@example.org
Received 4 December, 2015
Revised 1 August, 2015
Accepted 31 August, 2015
The article submitted does not contain information about medical device(s)/drug(s). The Danish Strategic Research Council (CESpine grant 2142–08–0017) funds were received in support of this work. Relevant financial activities outside the submitted work: consultancy, employment, and grants.